Buccal micronucleus cytome biomarkers may be associated with Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive degenerative dis-order of the brain and is the commonest form of dementia. A buccal cytome assay was used to measure ratios of buc-cal cell populations and micronuclei in clinically diagnosed Alzheimer’s patients compared to age and gender-matched controls. Frequencies of basal cells (P < 0.0001), condensed chromatin cells (P < 0.0001) and karyorrhectic cells (P < 0.0001) were found to be significantly lower in Alzheimer’s patients. These changes may reflect alterations in the cellular kinetics or structural profile of the buccal mucosa, and may be useful as potential biomarkers in identifying individuals with a high risk of developing AD. The odds ratio of being diagnosed with AD for those in-dividuals with a basal cell plus karyorrhectic cell fre-quency <41 per 1000 cells is 140, with a specificity of 97% and sensitivity of 82%. These promising results need to be replicated in larger studies and in cohorts of other neurodegenerative disorders to determine specificity of changes to Alzheimer’s patients